DRG Epidemiology's coverage of Myasthenia Gravis comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of Myasthenia Gravis for each country, as well as annualized case counts projected to the national population.
Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the other countries covered in this report.
DRG Epidemiology's Myasthenia Gravis forecast will answer the following questions:
How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of Myasthenia Gravis over the forecast period?
All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
In total, DRG Epidemiology forecasts one Myasthenia Gravis patient populations for Asia Pacific, that is:
Prevalence of Myasthenia Gravis per 100,000 Among People of All Ages in 2020 and 2030ttttttttt
Relative Sizes of the Factors Contributing to the Trend in Prevalent Cases of Myasthenia Gravis over the Next Ten Yearstttttttttttttt
Epidemiology data
Methods
Diagnosed Prevalent cases
Reference Materials
Literature Review
Studies Included in the Analysis of Myasthenia Gravis
Studies Excluded from the Analysis of Myasthenia Gravis
Risk/Protective Factors
Risk/Protective Factors for Myasthenia Gravis
Bibliography
Glossary
Nishant Kumar, M.P.H.
Nishant Kumar, M.P.H., is a senior director on the Epidemiology team at Clarivate. His areas of expertise are oncology and CNS diseases, including Alzheimer’s disease and dementia. His key interests in oncology are modeling disease progression and drug-treatable incident and prevalent populations. Previously, Mr. Kumar sized patient populations for rare and niche diseases, such as graft-versus-host disease and Duchenne muscular dystrophy. He earned his M.P.H. with a concentration in epidemiology and statistics from King’s College in London and a B.Sc. (Honors) in medical studies from the University of Birmingham.
